Navigation Links
Terahertz imaging may reduce breast cancer surgeries

rom 22 women who underwent either wide local excision or mastectomy to remove breast cancer. All samples were first sliced and imaged with terahertz light, and then submitted for histopathologic analysis. Imaging took less than five minutes.

"There were substantial differences in the optical properties of normal and diseased tissue," Dr. Wallace said. The size and shape of the diseased regions at terahertz imaging were compared with those at histopathologic examination, with good results. All but three samples yielded invasive cancers. In total, there were two invasive lobular carcinomas, 14 invasive ductal carcinomas, three mixed invasive ductal and lobular carcinomas, two cases of pure ductal carcinoma in situ and one dense radial scar.

In breast cancer excision surgery, the aim is to remove the entire tumor with an adequate margin of normal tissue, while minimizing the amount of healthy tissue being removed. If a histopathologist analyzes the tissue and finds tumor at or near the edges, this indicates that there is a higher chance of cancer recurrence. A second operation is required to remove more tissue, involving additional hospital resources and increased risk of patient morbidity. Thus, there is a clinical need to accurately define the margins of the tumor during surgery.


'"/>

Source:Radiological Society of North America


Page: 1 2

Related biology news :

1. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
2. Duke engineers develop new 3-D cardiac imaging probe
3. Confocal imaging promises early detection of skin cancer
4. Newer imaging techniques may lead to over-treatment
5. Researchers use 3-D imaging system to unveil swimming behavior of microscopic plankton
6. Microscopic brain imaging in the palm of your hand
7. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
8. Purdues gold nanorods brighten future for medical imaging
9. PET imaging reveals the immune system at work
10. New technique puts brain-imaging research on its head
11. T-rays: New imaging technology spotlighted by American Chemical Society

Post Your Comments:
(Date:11/23/2009)... Two new studies reveal in unprecedented detail h...assemble new proteins and guide them toward their ...molecular dynamics flexible fitting (MDFF) to exam...nent molecular partners. , The first study, in ... concerns the intimate signaling between the ribos...
(Date:11/23/2009)...stitute of General Medical Sciences (NIGMS), part ...esting $42.3 million for grants in scientific area... developed the GO grant program to stimulate biome...d by the American Recovery and Reinvestment Act (R...t promise to have a significant impact on a field ...
(Date:11/23/2009)...s available in German . , A bit of imaginat... be a bad thing. It could help to add data from ar...ever, it must do so constructively. In order to in...th more than just imagination, physicists at the M...ed a theory of spatial perception called informati...
Breaking Biology News(10 mins):Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 496 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 196 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 296 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 396 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 496 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 596 Week Safety and Efficacy Findings Presented for INTELENCE 28TM 29 28etravirine 29 As Part of HIV Combination Therapy 52098 6New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 1New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 2New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 3New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 4New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 5New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 6New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 7New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 8New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 1New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 2New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 3New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 4New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 5New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine 28TDF FTC 29 Versus Boosted Protease Inhibitor Regimen of Atazanavir Rito 4747 6
...ch Professor Benjamin Cravatt, Ph.D., is being pub...Biological Chemistry. , The new study describes a ...d-for the biosynthesis of neurotransmitter lipids,...dogenous cannabinoid ("endocannabinoid") anandamid...(Abh4) in areas such as the central nervous system...
...righteningly large if only there was a greater con...udes. The study adds support to the theory that so...oic period because they had a much richer oxygen s...er. , The study, "No giants today: tracheal oxygen...presented Oct. 10 and 11 at Comparative Physiology...
...earch-and-destroy quest for weeds, will soon be mo... fields at the University of Illinois. What,s more...ile significantly reducing herbicide use. , The ro...ll cameras mounted on a frame on top of the machin...human, said Lei Tian, agricultural engineer at the...
Other Biology News:Nanotechnology propels advances in regenerative medicine research 2Giant insects might reign if only there was more oxygen in the air 2Giant insects might reign if only there was more oxygen in the air 3New system could drastically reduce herbicide use 2New system could drastically reduce herbicide use 3
(Date:11/23/2009)...ink of it as origami very high-tech origami. , R...loped a technique for fabricating three-dimensiona... films by coupling photolithography and a self-fol...The films, only a few microns thick, offer mechani...pieces of the same material. , "This is a complet...
(Date:11/23/2009)...PRNewswire-FirstCall/--NeogenCorporation(Nasdaq: N...lectedtoNeogen,sBoardofDirectorsatthecompany,srece...ethan40yearsofexperienceinthefood,agriculture,andt...orofagriculturaleconomicsatVirginiaTechUniversity....chiefagriculturenegotiatorwiththerankofambassador....
(Date:11/23/2009)...v.23/PRNewswire/--PearlTherapeuticsInc.,abiopharma...treatmentofchronicrespiratorydiseases,todayannounc...irectors.Mr.Rosenhas25yearsofexperienceinthepharma...esatGileadSciencesandALZACorporation.Hisappointmen... ,, "Howiebringsawealthofproductdevelopment,com...
(Date:11/20/2009)... Dendreon Corporation (Na...nd Drug Administration (FDA) provided written ackn...icense Application (BLA) for PROVENGE® (sipul...gned a Prescription Drug User Fee Act (PDUFA) date...Dendreon,s amended BLA. Dendreon is seeking licen...
Breaking Biology Technology:Water droplets direct self-assembly process in thin-film materials 2Richard T. Crowder Joins Neogen's Board of Directors 2Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
...yne, Inc.,(Nasdaq: RDYN ) announced today that it...2008 at 4:45 P.M. ET to report first quarter 2008,... Replidyne will host its,annual shareholder meetin...n Louisville, CO., Earnings conference call in...resident and CEO, and other members of Replidyne,s...
...Points from the First Quarter of 2007 to ...to Launch Newest Generation of Laser Lipolysis ...Mass., April 29 Cynosure, Inc.,(Nasdaq: CYNO ), ...ray of,light-based aesthetic treatment systems, to... the quarter ended March 31, 2008., First-Quarter...
...merica,Inc. (OTC Bulletin Board: CBAI), the umbili...tp://www.cordblood-america.com ) focused on,bring...ilies nationwide and,internationally, today report...erview with Francis Gaskins, said 2007 acquisition...d a 600 percent increase in gross profits., "We w...
Other Biology Technology:Replidyne to Report First Quarter 2008 Earnings 2Replidyne to Report First Quarter 2008 Earnings 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 2Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 3Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 4Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 5Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 6Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 7Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 8Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 9Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 10Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth 11Cord Blood America CEO Matthew Schissler Says Operations Significantly Streamlined 2
Streptavidin, PE conjugated/tagged from Invitrogen
Supercoiled DNA Ladder from Invitrogen
GIBCO RPMI Medium 1640; powder from Invitrogen
Rabbit Anti-Human Parathyroid Hormone Receptor 2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: